ESALF News and Press, Eisai Co Ltd From 01/15/24

Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024 TOKYO, Jan 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of oncology research at two upcoming medical meetings taking place in-person in San Francisco, California and ...

2024-01-11 05:46:14 ET Biogen ( NASDAQ: BIIB ) and its Japanese partner Eisai ( OTCPK:ESALF ) have filed a marketing authorization application for their breakthrough Alzheimer's therapy, called Leqembi (lecanemab), in the EU. The application to the European Medicines Agency ...

Eisai: The Scientific Advisory Group (SAG) to Convene to Discuss the Marketing Authorization Application for lecanemab in the EU TOKYO, Jan 11, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the Scientific Advisory Group (SAG) will convene to discuss the marketing auth...

Eisai: "LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China TOKYO and CAMBRIDGE, Mass., Jan 10, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclona...

2024-01-09 05:30:25 ET Biogen ( NASDAQ: BIIB ) and its Japanese partner Eisai ( OTCPK:ESALF ) announced on Tuesday market approval for their breakthrough Alzheimer's therapy, called Leqembi, in China. Leqembi (lecanemab), a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

Development of Prediction Model for Brain Amyloid-Beta Accumulation Using Wristband Sensor TOKYO, Dec 29, 2023 - (JCN Newswire) - Oita University and Eisai Co., Ltd. (Eisai) hereby announce the development of the world's first machine learning model to predict amyloid beta*1 (A&...

2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tasurgratinib for Biliary Tract Cancer with Fgfr2 Gene Fusion TOKYO, Dec 19, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan f...

Eisai and Mizuho Sign Sustainability-Linked Loan Agreement TOKYO, Dec 14, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Mizuho Bank, Ltd. announced today that the companies have signed a sustainability-linked syndicated loan agreement, which comes into effect today. Sustainability...

"LEQEMBI Intravenous Infusion"Lecanemab) for the Treatment of Alzheimer's Disease to be Launched in Japan on December 20 TOKYO and CAMBRIDGE, Mass., Dec 14, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (...